Gene therapy for breast and ovarian cancer with BRCA1

David L. Tait, Roy A. Jensen, Jeffrey T. Holt, David H. Johnson, Julie Gralow, Mary Claire King

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

As an initial step toward gene therapy for ovarian cancer, we conducted a Phase 1 trial to assess the pharmacokinetics and toxicity of intraperitoneal BRCA1sv retroviral vector therapy. Gene transfer and expression were documented by PCR, southern blot, RT-PCR and nuclease protection assays. Pharmacokinetics were assessed by PCR and southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of twelve patients developed an acute sterile peritonitis which spontaneously resolved within 48 hours. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to four months. Eight patients showed stable disease for 4 to 16 weeks. Three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). Ovarian cancer may provide an imporant model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by intraperitoneal therapy.

Original languageEnglish (US)
Pages (from-to)89-98
Number of pages10
JournalBreast Disease
Volume10
Issue number1-2
StatePublished - Apr 1998

Fingerprint

Genetic Therapy
Ovarian Neoplasms
Breast Neoplasms
Southern Blotting
Polymerase Chain Reaction
Nuclease Protection Assays
Pharmacokinetics
Neoplasms
Peritonitis
Reoperation
Antibody Formation
Gene Expression
Antibodies
DNA
Therapeutics
Proteins

ASJC Scopus subject areas

  • Surgery

Cite this

Tait, D. L., Jensen, R. A., Holt, J. T., Johnson, D. H., Gralow, J., & King, M. C. (1998). Gene therapy for breast and ovarian cancer with BRCA1. Breast Disease, 10(1-2), 89-98.

Gene therapy for breast and ovarian cancer with BRCA1. / Tait, David L.; Jensen, Roy A.; Holt, Jeffrey T.; Johnson, David H.; Gralow, Julie; King, Mary Claire.

In: Breast Disease, Vol. 10, No. 1-2, 04.1998, p. 89-98.

Research output: Contribution to journalArticle

Tait, DL, Jensen, RA, Holt, JT, Johnson, DH, Gralow, J & King, MC 1998, 'Gene therapy for breast and ovarian cancer with BRCA1', Breast Disease, vol. 10, no. 1-2, pp. 89-98.
Tait DL, Jensen RA, Holt JT, Johnson DH, Gralow J, King MC. Gene therapy for breast and ovarian cancer with BRCA1. Breast Disease. 1998 Apr;10(1-2):89-98.
Tait, David L. ; Jensen, Roy A. ; Holt, Jeffrey T. ; Johnson, David H. ; Gralow, Julie ; King, Mary Claire. / Gene therapy for breast and ovarian cancer with BRCA1. In: Breast Disease. 1998 ; Vol. 10, No. 1-2. pp. 89-98.
@article{1ffdedb231c644bd9a864a19ee8ccb12,
title = "Gene therapy for breast and ovarian cancer with BRCA1",
abstract = "As an initial step toward gene therapy for ovarian cancer, we conducted a Phase 1 trial to assess the pharmacokinetics and toxicity of intraperitoneal BRCA1sv retroviral vector therapy. Gene transfer and expression were documented by PCR, southern blot, RT-PCR and nuclease protection assays. Pharmacokinetics were assessed by PCR and southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of twelve patients developed an acute sterile peritonitis which spontaneously resolved within 48 hours. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to four months. Eight patients showed stable disease for 4 to 16 weeks. Three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). Ovarian cancer may provide an imporant model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by intraperitoneal therapy.",
author = "Tait, {David L.} and Jensen, {Roy A.} and Holt, {Jeffrey T.} and Johnson, {David H.} and Julie Gralow and King, {Mary Claire}",
year = "1998",
month = "4",
language = "English (US)",
volume = "10",
pages = "89--98",
journal = "Breast Disease",
issn = "0888-6008",
publisher = "IOS Press",
number = "1-2",

}

TY - JOUR

T1 - Gene therapy for breast and ovarian cancer with BRCA1

AU - Tait, David L.

AU - Jensen, Roy A.

AU - Holt, Jeffrey T.

AU - Johnson, David H.

AU - Gralow, Julie

AU - King, Mary Claire

PY - 1998/4

Y1 - 1998/4

N2 - As an initial step toward gene therapy for ovarian cancer, we conducted a Phase 1 trial to assess the pharmacokinetics and toxicity of intraperitoneal BRCA1sv retroviral vector therapy. Gene transfer and expression were documented by PCR, southern blot, RT-PCR and nuclease protection assays. Pharmacokinetics were assessed by PCR and southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of twelve patients developed an acute sterile peritonitis which spontaneously resolved within 48 hours. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to four months. Eight patients showed stable disease for 4 to 16 weeks. Three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). Ovarian cancer may provide an imporant model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by intraperitoneal therapy.

AB - As an initial step toward gene therapy for ovarian cancer, we conducted a Phase 1 trial to assess the pharmacokinetics and toxicity of intraperitoneal BRCA1sv retroviral vector therapy. Gene transfer and expression were documented by PCR, southern blot, RT-PCR and nuclease protection assays. Pharmacokinetics were assessed by PCR and southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of twelve patients developed an acute sterile peritonitis which spontaneously resolved within 48 hours. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to four months. Eight patients showed stable disease for 4 to 16 weeks. Three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). Ovarian cancer may provide an imporant model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by intraperitoneal therapy.

UR - http://www.scopus.com/inward/record.url?scp=0031944672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031944672&partnerID=8YFLogxK

M3 - Article

C2 - 15687552

AN - SCOPUS:0031944672

VL - 10

SP - 89

EP - 98

JO - Breast Disease

JF - Breast Disease

SN - 0888-6008

IS - 1-2

ER -